Please use this identifier to cite or link to this item: https://doi.org/10.2147/DDDT.S170518
Title: Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis
Authors: Hu, Y.-B.
Liu, X.-Y. 
Zhan, W.
Keywords: Farnesoid X receptor agonist
INT-767
Nonalcoholic steatohepatitis
Transmembrane g protein-coupled receptor 5
Issue Date: 2018
Publisher: Dove Medical Press Ltd.
Citation: Hu, Y.-B., Liu, X.-Y., Zhan, W. (2018). Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis. Drug Design, Development and Therapy 12 : 2213-2221. ScholarBank@NUS Repository. https://doi.org/10.2147/DDDT.S170518
Rights: Attribution-NonCommercial 4.0 International
Abstract: Introduction: Nonalcoholic steatohepatitis (NASH) is largely driven by the dysregulation of liver metabolism and inflammation. Bile acids and their receptor Farnesoid X receptor (FXR) play a critical role in the disease development. Here, we investigated whether INT-767, the newly-identified dual FXR/TGR5 agonist, can protect rat from liver injury during NASH. Materials and methods: NASH model was established by feeding the male SD rats with high-fat diet for 16 weeks. INT-767 was given by gavage to NASH rats from week 13 to week 16. At the end of 16 weeks, liver and serum were harvested, and bile acids, glucose and lipid metabolism, liver injury and histological features were evaluated. Results: INT-767 treatment significantly alleviates high-fat caused liver damage characterized with lipid accumulation and hepatic infiltration of immune cells. INT-767 robustly restores the lipid, glucose metabolism to normal level, attenuates insulin resistance through upregulating FXR level and reverting the dysregulation of its target genes in liver metabolism. Molecularly INT-767 also attenuates the pro-inflammatory response by suppression of TNF-? and NF-?B signaling pathway. Conclusion: INT-767 may be an attractive candidate for a potential novel strategy on the treatment of NASH. © 2018 Hu et al.
Source Title: Drug Design, Development and Therapy
URI: https://scholarbank.nus.edu.sg/handle/10635/206484
ISSN: 1177-8881
DOI: 10.2147/DDDT.S170518
Rights: Attribution-NonCommercial 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_2147_DDDT_S170518.pdf2.22 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

24
checked on Jan 25, 2022

Page view(s)

10
checked on Jan 27, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons